Election Interference by Injection? Pfizer Accused of Slowing Vaccine Trials to Sway 2020 Vote

Timing, it seems, was everything.

New allegations suggest that senior Pfizer executives may have intentionally delayed clinical trial data for the COVID-19 vaccine in late 2020, potentially to influence the outcome of the U.S. presidential election. A congressional letter dated May 15, 2025, addressed to Pfizer CEO Dr. Albert Bourla, outlines claims made by GSK to a federal committee that Dr. Philip Dormitzer, a high-ranking Pfizer official at the time, told GSK employees that “the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year.”

The suggestion is not that results were hidden after being obtained—but that the trials themselves were deliberately slowed to prevent results from being finalized before Election Day.

A separate quote cited by the committee amplifies the implication of political manipulation:

“Let’s just say it wasn’t a coincidence, the timing of the vaccine.”

GSK reportedly made clear that this was about delaying the pace of testing itself, not just the release of data. The committee noted this distinction, stating the issue was “slowing down results before disclosure became necessary,” rather than simply withholding completed findings.

The seriousness of the claim prompted the congressional committee to request additional documents from Pfizer, citing concerns that Dormitzer and other senior executives may have “conspired to withhold public health information to influence the 2020 presidential election.”

If proven true, these allegations could mark a watershed scandal at the intersection of pharmaceutical power and political influence—where science was not just guided by data, but potentially by election calendars.